AVANAFIL + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
Conditions
Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
Trial Timeline
Jul 1, 2015 → Mar 1, 2016
NCT ID
NCT02503306About AVANAFIL + placebo
AVANAFIL + placebo is a phase 3 stage product being developed by Sanofi for Sexual Function and Fertility Disorders NEC-Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT02503306. Target conditions include Sexual Function and Fertility Disorders NEC-Erectile Dysfunction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02503306 | Phase 3 | Completed |
Competing Products
18 competing products in Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| Gardasil Vaccine | Merck | Pre-clinical | 23 |
| sildenafil | Pfizer | Approved | 84 |
| sildenafil | Pfizer | Phase 2 | 51 |
| CP-866,087 + CP-866,087 + CP-866,087 + Placebo | Pfizer | Phase 2 | 51 |
| PF-00446687 + Placebo | Pfizer | Phase 2 | 51 |
| Bremelanotide | Pfizer | Phase 2 | 51 |
| Sildenafil 100 mg + Placebo | Pfizer | Phase 2 | 51 |
| Alfuzosin | Sanofi | Approved | 84 |
| Levitra (Vardenafil, BAY38-9456) + Placebo | Bayer | Approved | 82 |
| Placebo + 0.5 mgTestosterone + 10 mg Buspirone | Brain Biotech | Phase 2 | 44 |
| Placebo + Testosterone + Buspirone hydrochloride | Brain Biotech | Phase 2 | 44 |
| Placebo + Sildenafil + Testosterone | Brain Biotech | Phase 2 | 44 |
| tibolone + estradiol-norethisterone | Organon | Phase 3 | 72 |
| Bremelanotide + Placebo | Palatin Technologies | Phase 3 | 69 |
| bremelanotide | Palatin Technologies | Phase 2 | 44 |
| Bremelanotide | Palatin Technologies | Phase 3 | 69 |
| EVO100 + Placebo | Evofem Biosciences | Phase 3 | 69 |